drugset / Trial / NCT04793620
Pertussis Acellular Vaccine Adjuvanted With TQL1055
RandomizedSequentialDouble-blindPrevention
Summary
This is a phase 1 study to evaluate the safety and immunogenicity of the semisynthetic saponin adjuvant TQL1055 administered in combination with an acellular pertussis vaccine.
Timeline
- Start
- 2021-04-06
- Primary completion
- 2021-08-23
- Completion
- 2022-02-14
Outcome
Outcome not reported
Stopped (Business): “financial constraints”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acellular pertussis vaccine | Vaccine | — | — |
| Subject | TQL1055 | Other / unclassified | — | — |